Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Capital good stocks lead the rally
Thu, 18 Apr 01:30 pm

Backed by strong buying sentiment, Indian share markets climbed higher in the post-noon trading session. Barring metal and IT, all the sectoral indices are trading positive. capital goods, consumer durables and banking stocks are the major gainers.

BSE-Sensex is up 149 points and NSE-Nifty is trading up 50 points. While BSE Mid Cap is up 0.4%, BSE Small Cap index is trading up by 0.3%. The rupee is trading at 54.0 to the US dollar.

According to the Commerce & Industry Ministry, the country's export turnover recorded a decline of 1.8% to $300.6 bn in FY13. Lower exports were due to fall in growth of engineering and textile sectors arising from slowdown in the global economy. Exports for FY13 were much lower than the export target of $360 bn set by the government for the year. The slump in exports has pushed up the trade deficit to $190.9 bn in FY13 from $183.4 bn in the previous year. With an aim to boost exports, the government has announced a number of steps. The government has extended the zero-duty Export Promotion Capital Goods (EPCG) Scheme beyond March 2013. This incentive programme would be available to all the sectors. Apart from this, the government has announced incentives for Special Economic Zones (SEZ's) to encourage exports.

Most of the Indian pharma stocks are trading in green with Wockhardt Ltd and Ranbaxy Laboratories being the leading gainers. Lupin Ltd (LUPL), announced that U.S Court of Appeals for the Federal Circuit has given verdict in the company's favour regarding the ongoing litigation on the Bayer's drug Yaz. Yaz is an oral contraceptive and Lupin is awaiting approval from USFDA (United States Food and Drug Administration). Lupin's generic Drospirenone and Ethinyl Estradiol Tablets (3 mg + 0.02 mg) is equivalent to Bayer AG's Yaz tablets. Reportedly, the total annual sales for branded and generic sales for the product stood at US$ 361 m. Lupin has already established portfolio in the oral contraceptive space. The approval and launch of Yaz generics in US market will be positive for the company. The stock of Lupin was trading up by 0.05%

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Capital good stocks lead the rally". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.